<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

New Personalized Vaccine Defeats Neoantigen Presenting Melanoma. How to Fight Fire with Fire

The ability of the immune system to detect cancer cells as foreign bodies is a longstanding concept known as immunosurveillance. This hypothesis has cyclically met the enthusiasm and skepticism of the scientific community because of the high toxicity of some immunotherapies. We are now beginning to understand that the immune system can be trained to specifically attack cancer cells with only minimal effects for the normal surrounding tissues. Scientists at the Washington University School of Medicine in St. Louis have recently published their results from the "First-in-People" clinical trial suggesting that a personalized anti-melanoma vaccine is possible and can elicit a powerful immune response against tumor cells.

Much like vaccines for infectious diseases, cancer vaccines typically deliver into the body bits of protein or other material (antigens) that trigger the activation of the immune system. But cancer vaccines have a poor record of success, mostly because the majority of the tumor antigens tested also appear in small amounts on healthy cells, and the immune system has mechanisms of tolerance to ignore them. Some cancer vaccines also contain interleukins, a class of molecules produced by a subtype of immune cells called dendritic cells (DC), which had been shown to reduce tumor progression. However interleukin systemic administration is very toxic at high doses and their delivery, as part of a cancer vaccine, has been limited.

But not all hope is lost. Thanks to the drop in DNA sequencing costs and to its increased speed and efficiency, it is now possible to devise a more promising kind of tumor antigens that take advantage of the high mutation rate characterizing a tumor’s DNA. Some of these mutations result in the production of novel small proteins, called neoantigens, exclusive to cancer cells that can be presented on their surface and may activate the response of the immune system.

Human immunologist Beatriz Carreno, trial leader Gerald Linette, and collaborators at Washington University studied three melanoma patients who relapsed following surgery. After sequencing each patient’s original melanoma DNA, they selected seven neoantigens unique to that person’s tumor that they found most likely to trigger an immune response and they exposed each patient’s harvested DC to this set of neoantigens. The resulting DC coated with specific neoantigens were shown to be able to activate T cells in vitro to kill melanoma, and were used to make personalized vaccines that were infused into patients who had already been treated with ipilimumab and had relapsed. Results from the “First-In-People” small clinical trial showed that patients either remained stable over a long period of time or became cancer free after the treatment. Researchers caution that it is too early to say whether the vaccines will be effective in the long term, as the study was designed to assess safety and immune response rather than efficacy of the vaccine as anticancer agent. However, none of the trial participants have experienced adverse effects from their personalized vaccines and the strength of immune response observed in the study suggests the idea is promising.

Due to the success reported so far, a Phase I vaccine trial enrolling six patients has now been approved by the FDA. If results from Phase I testing confirm the vaccines efficacy, they could be used to stimulate a post-surgery anticancer immune response to destroy any remaining cancer cells, preventing recurrence.

At Crown Bioscience we are excited to see more new immunotherapies moving into clinical trial, especially for cancer types that need new treatment options. Crown Bioscience support research in immune therapies with a range of immunotherapy platforms (with either murine or human immunity) including our MuPrime™ (the murine version of HuPrime® which is the world’s largest collection of well-characterized and validated Patient-Derived Xenograft models), HuMice (humanized mice produced through inoculating human hematopoietic cells into immunocompromised mice), and MiXeno(creating transient human immunity by mixing human peripheral blood mononucleated cells with xenograft models). We support melanoma research through the use of our clinically relevant Xenograft and Patient-Derived Xenograft models available for drug discovery and translational sciences.

Contact us today at busdev@crownbio.com to discover how we can transform your immunotherapy and melanoma research today.


Related Posts